Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma

Brian T. Hill, John Sweetenham

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and responds to standard treatment with chemoimmunotherapy in most patients. Standard prognostic scoring systems such as the International Prognostic Index (IPI) are useful for risk stratification, but are unreliable in predicting outcomes in individual patients because of the biologic heterogeneity of this disease. Gene expression profiling has revealed molecular subtypes of DLBCL: those derived from the lymph node germinal center (GCB) and others derived from an activated B-cell (ABC). A third entity, primary mediastinal B-cell lymphoma (unclassifiable DLBCL), displays pathobiologic features distinct from ABC and GCB subtypes. Patients with ABC-DLBCL have inferior progression-free survival and overall survival relative to those with the GCB subtype. In conclusion, molecular subtyping is a powerful tool for discriminating cases of DLBCL into groups that display very disparate biology and clinical outcomes. Although immunohistochemistry (IHC)-based algorithms predict both the molecular subtype as defined by gene expression profiling and clinical outcomes with reasonable concordance, not all experienced centers have been able to reproduce these findings. As techniques to subclassify DLBCL become universally adopted, large prospective trials will be needed to confirm the benefit of therapy tailored to molecular subtype.

Original languageEnglish (US)
Pages (from-to)763-769
Number of pages7
JournalLeukemia and Lymphoma
Volume53
Issue number5
DOIs
StatePublished - May 1 2012
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
B-Lymphocytes
Gene Expression Profiling
B-Cell Lymphoma
Germinal Center
Disease-Free Survival
Lymphoma
Lymph Nodes
Immunohistochemistry
Survival
Therapeutics

Keywords

  • activated B-cell
  • Diffuse large B-cell lymphoma
  • germinal center
  • molecular subtype

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. / Hill, Brian T.; Sweetenham, John.

In: Leukemia and Lymphoma, Vol. 53, No. 5, 01.05.2012, p. 763-769.

Research output: Contribution to journalReview article

@article{e4a49d0b77d943389c5ddf6bea21ff8c,
title = "Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma",
abstract = "Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and responds to standard treatment with chemoimmunotherapy in most patients. Standard prognostic scoring systems such as the International Prognostic Index (IPI) are useful for risk stratification, but are unreliable in predicting outcomes in individual patients because of the biologic heterogeneity of this disease. Gene expression profiling has revealed molecular subtypes of DLBCL: those derived from the lymph node germinal center (GCB) and others derived from an activated B-cell (ABC). A third entity, primary mediastinal B-cell lymphoma (unclassifiable DLBCL), displays pathobiologic features distinct from ABC and GCB subtypes. Patients with ABC-DLBCL have inferior progression-free survival and overall survival relative to those with the GCB subtype. In conclusion, molecular subtyping is a powerful tool for discriminating cases of DLBCL into groups that display very disparate biology and clinical outcomes. Although immunohistochemistry (IHC)-based algorithms predict both the molecular subtype as defined by gene expression profiling and clinical outcomes with reasonable concordance, not all experienced centers have been able to reproduce these findings. As techniques to subclassify DLBCL become universally adopted, large prospective trials will be needed to confirm the benefit of therapy tailored to molecular subtype.",
keywords = "activated B-cell, Diffuse large B-cell lymphoma, germinal center, molecular subtype",
author = "Hill, {Brian T.} and John Sweetenham",
year = "2012",
month = "5",
day = "1",
doi = "10.3109/10428194.2011.626882",
language = "English (US)",
volume = "53",
pages = "763--769",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma

AU - Hill, Brian T.

AU - Sweetenham, John

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and responds to standard treatment with chemoimmunotherapy in most patients. Standard prognostic scoring systems such as the International Prognostic Index (IPI) are useful for risk stratification, but are unreliable in predicting outcomes in individual patients because of the biologic heterogeneity of this disease. Gene expression profiling has revealed molecular subtypes of DLBCL: those derived from the lymph node germinal center (GCB) and others derived from an activated B-cell (ABC). A third entity, primary mediastinal B-cell lymphoma (unclassifiable DLBCL), displays pathobiologic features distinct from ABC and GCB subtypes. Patients with ABC-DLBCL have inferior progression-free survival and overall survival relative to those with the GCB subtype. In conclusion, molecular subtyping is a powerful tool for discriminating cases of DLBCL into groups that display very disparate biology and clinical outcomes. Although immunohistochemistry (IHC)-based algorithms predict both the molecular subtype as defined by gene expression profiling and clinical outcomes with reasonable concordance, not all experienced centers have been able to reproduce these findings. As techniques to subclassify DLBCL become universally adopted, large prospective trials will be needed to confirm the benefit of therapy tailored to molecular subtype.

AB - Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and responds to standard treatment with chemoimmunotherapy in most patients. Standard prognostic scoring systems such as the International Prognostic Index (IPI) are useful for risk stratification, but are unreliable in predicting outcomes in individual patients because of the biologic heterogeneity of this disease. Gene expression profiling has revealed molecular subtypes of DLBCL: those derived from the lymph node germinal center (GCB) and others derived from an activated B-cell (ABC). A third entity, primary mediastinal B-cell lymphoma (unclassifiable DLBCL), displays pathobiologic features distinct from ABC and GCB subtypes. Patients with ABC-DLBCL have inferior progression-free survival and overall survival relative to those with the GCB subtype. In conclusion, molecular subtyping is a powerful tool for discriminating cases of DLBCL into groups that display very disparate biology and clinical outcomes. Although immunohistochemistry (IHC)-based algorithms predict both the molecular subtype as defined by gene expression profiling and clinical outcomes with reasonable concordance, not all experienced centers have been able to reproduce these findings. As techniques to subclassify DLBCL become universally adopted, large prospective trials will be needed to confirm the benefit of therapy tailored to molecular subtype.

KW - activated B-cell

KW - Diffuse large B-cell lymphoma

KW - germinal center

KW - molecular subtype

UR - http://www.scopus.com/inward/record.url?scp=84859993680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859993680&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.626882

DO - 10.3109/10428194.2011.626882

M3 - Review article

C2 - 21992676

AN - SCOPUS:84859993680

VL - 53

SP - 763

EP - 769

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -